These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 21724302)

  • 41. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
    Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
    Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
    Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
    Eskow Jaunarajs KL; Standaert DG; Viegas TX; Bentley MD; Fang Z; Dizman B; Yoon K; Weimer R; Ravenscroft P; Johnston TH; Hill MP; Brotchie JM; Moreadith RW
    Mov Disord; 2013 Oct; 28(12):1675-82. PubMed ID: 24014074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study.
    Pellicano C; Benincasa D; Fanciulli A; Latino P; Giovannelli M; Pontieri FE
    Eur J Med Res; 2013 Dec; 18(1):60. PubMed ID: 24360350
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
    Takahashi H; Nogawa S; Tachibana H; Kawamura J; Abe T; Ogino Y; Kashihara K; Hamada T; Kowa H;
    J Int Med Res; 2008; 36(1):106-14. PubMed ID: 18230274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease.
    Contin M; Lopane G; Mohamed S; Calandra-Buonaura G; Capellari S; De Massis P; Nassetti S; Perrone A; Riva R; Sambati L; Scaglione C; Cortelli P
    Parkinsonism Relat Disord; 2019 Apr; 61():111-117. PubMed ID: 30446407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
    Seeman P
    Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
    Tulloch IF
    Neurology; 1997 Jul; 49(1 Suppl 1):S58-62. PubMed ID: 9222275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
    Zesiewicz TA; Martinez-Martin P
    Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
    Rascol O
    J Neural Transm Suppl; 1999; 55():33-45. PubMed ID: 10335491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The complex molecular pharmacology of the dopamine D
    Ferraiolo M; Hermans E
    Pharmacol Ther; 2023 May; 245():108392. PubMed ID: 36958527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.
    Thorlund K; Wu P; Druyts E; Eapen S; Mills EJ
    Neuropsychiatr Dis Treat; 2014; 10():767-76. PubMed ID: 24855362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease.
    van Wamelen DJ; Grigoriou S; Chaudhuri KR; Odin P
    J Parkinsons Dis; 2018; 8(s1):S65-S72. PubMed ID: 30584160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
    Ogawa N
    Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
    Shen T; Ye R; Zhang B
    Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of ropinirole prolonged release in Parkinson's disease.
    Nashatizadeh MM; Lyons KE; Pahwa R
    Clin Interv Aging; 2009; 4():179-86. PubMed ID: 19503779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.
    Adler CH; Sethi KD; Hauser RA; Davis TL; Hammerstad JP; Bertoni J; Taylor RL; Sanchez-Ramos J; O'Brien CF
    Neurology; 1997 Aug; 49(2):393-9. PubMed ID: 9270567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials.
    Zhou CQ; Lou JH; Zhang YP; Zhong L; Chen YL; Lu FJ; Peng GG
    CNS Neurosci Ther; 2014 Apr; 20(4):368-76. PubMed ID: 24588909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pramipexole extended release: in Parkinson's disease.
    Chwieduk CM; Curran MP
    CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.